Application Nr Approved Date Route Status External Links
ANDA076132 None Oral None Google , Wikipedia , PubMed , DailyMed , Raw OpenFDA , ECHA , ToxNet , JECFA , FAO , 21 CFR

Indications and Purposes

Indications And Usage Rimantadine Hydrochloride Tablet Is Indicated For The Prophylaxis And Treatment Of Illness Caused By Various Strains Of Influenza A Virus In Adults (17 Years And Older). Rimantadine Hydrochloride Tablet Is Indicated For Prophylaxis Against Influenza A Virus In Children (1 Year To 16 Years Of Age). Prophylaxis In Controlled Studies Of Children (1 Year To 16 Years Of Age), Healthy Adults (17 Years And Older), And Elderly Patients (65 Years Of Age And Older), Rimantadine Hydrochloride Has Been Shown To Be Safe And Effective In Preventing Signs And Symptoms Of Infection Caused By Various Strains Of Influenza A Virus. Since Rimantadine Hydrochloride Does Not Completely Prevent The Host Immune Response To Influenza A Infection, Individuals Who Take This Drug May Still Develop Immune Responses To Natural Disease Or Vaccination And May Be Protected When Later Exposed To Antigenically-Related Viruses. Following Vaccination During An Influenza Outbreak, Rimantadine Hydrochloride Prophylaxis Should Be Considered For The 2 To 4 Week Time Period Required To Develop An Antibody Response. However, The Safety And Effectiveness Of Rimantadine Hydrochloride Prophylaxis Have Not Been Demonstrated For Longer Than 6 Weeks. Treatment Rimantadine Hydrochloride Therapy Should Be Considered For Adults (17 Years And Older) Who Develop An Influenza-Like Illness During Known Or Suspected Influenza A Infection In The Community. When Administered Within 48 Hours After Onset Of Signs And Symptoms Of Infection Caused By Influenza A Virus Strains, Rimantadine Hydrochloride Has Been Shown To Reduce The Duration Of Fever And Systemic Symptoms. The Following Points Should Be Considered Before Initiating Treatment Or Prophylaxis With Rimantadine Hydrochloride: Rimantadine Hydrochloride Is Not A Substitute For Early Vaccination On An Annual Basis As Recommended By The Centers For Disease Control And Prevention Advisory Committee On Immunization Practices. Influenza Viruses Change Over Time. Emergence Of Resistance Mutations Could Decrease Drug Effectiveness. Other Factors (For Example, Changes In Viral Virulence) Might Also Diminish Clinical Benefit Of Antiviral Drugs. Prescribers Should Consider Available Information On Influenza Drug Susceptibility Patterns And Treatment Effects When Deciding Whether To Use Rimantadine Hydrochloride.

All Formulated Excipients (0 Total)

None

Active Ingredients ( 1 Total)

Name Structure ZINC ID(s)
1. Rimantadine Hydrochloride RIMANTADINE HYDROCHLORIDE ZINC3831429

Comments